This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): A-60444
Description: A-60444 a first-in-class therapy in development for the treatment of respiratory syncytial virus (RSV) infections. It works by inhibiting the nucleocapsid (N) protein of the virus, which is involved in replication. RSV is the most common respiratory virus in infants.
Deal Structure: Novartis signed an exclusive global license agreement with Arrow Therapeutics in June 2005 for A-60444.
Under the terms of the agreement, Novartis obtains the rights to develop, manufacture and commercialize A-60444 as well as rights to back-up compounds and a right of first negotiation on follow-up compounds.
In March 2007, the acquisition of Arrow Therapeutics by AstraZeneca was closed.
Partners: AstraZeneca PLC
Additional information available to subscribers only: